Heart risk link to smoking drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An anti-smoking pill used by thousands of Britons increases the risk of heart attacks and stroke by at least 72 per cent, research has suggested.
Champix (varenicline) is a prescription-only medicine that works by citting cravings and accounted for 955,242 prescriptions in England in 2010. Fears had previously been raised after patients reported depression, suicidal thoughts and anxiety, but a new study has said the drug is associated with a "significantly increased risk of serious adverse cardiovascular events", such as heart attack and stroke, when compared with placebo.
The research, published in the Canadian Medical Association Journal, analysed data for more than 8,000 people from 14 medical trials. A total of 52 of 4,908 people on the drug had adverse events compared with 27 of 3,308 people on placebo, though there was no difference in death rates.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments